Sign In
Buy DNLI
$19.66
+0.310 (+1.60%)
At Close: Jun 03, 2026
Denali Therapeutics (NASDAQ:DNLI) Lowered to Buy at ValuEngine
05:42am, Saturday, 02'nd May 2020
Denali Therapeutics (NASDAQ:DNLI) was downgraded by investment analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a note issued to investors on Friday, ValuEngine reports.
Does The Denali Therapeutics Inc. (NASDAQ:DNLI) Share Price Fall With The Market?
02:15pm, Friday, 01'st May 2020
If you're interested in Denali Therapeutics Inc. (NASDAQ:DNLI), then you might want to consider its beta (a measure of...
Bank of America Corp DE Sells 18,580 Shares of Denali Therapeutics Inc (NASDAQ:DNLI)
08:50am, Thursday, 30'th Apr 2020
Bank of America Corp DE cut its holdings in shares of Denali Therapeutics Inc (NASDAQ:DNLI) by 42.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities
Denali Therapeutics (NASDAQ:DNLI) Trading 5% Higher
08:24am, Sunday, 26'th Apr 2020
Denali Therapeutics Inc (NASDAQ:DNLI)’s stock price traded up 5% on Friday . The stock traded as high as $22.92 and last traded at $22.77, 272,489 shares traded hands during trading. A decline of 60
Analysts Anticipate Denali Therapeutics Inc (NASDAQ:DNLI) Will Post Quarterly Sales of $5.93 Million
06:00am, Sunday, 26'th Apr 2020
Analysts expect Denali Therapeutics Inc (NASDAQ:DNLI) to announce $5.93 million in sales for the current quarter, Zacks reports. Six analysts have provided estimates for Denali Therapeutics’ earning
Denali Therapeutics Inc (NASDAQ:DNLI) Short Interest Down 5.9% in March
07:40am, Friday, 24'th Apr 2020
Denali Therapeutics Inc (NASDAQ:DNLI) was the recipient of a large decrease in short interest during the month of March. As of March 31st, there was short interest totalling 8,910,000 shares, a decrea
Head-To-Head Contrast: BIONDVAX PHARMA/S (NASDAQ:BVXV) vs. Denali Therapeutics (NASDAQ:DNLI)
05:30am, Monday, 20'th Apr 2020
BIONDVAX PHARMA/S (NASDAQ:BVXV) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their a
Were Hedge Funds Right About Edgewell Personal Care Company (EPC)?
01:36pm, Saturday, 18'th Apr 2020
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
Were Hedge Funds Right About Park National Corporation (PRK)?
01:36pm, Saturday, 18'th Apr 2020
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
Were Hedge Funds Right About Core Laboratories N.V. (CLB)?
01:35pm, Saturday, 18'th Apr 2020
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
Were Hedge Funds Right About Mobile Mini Inc (MINI)?
01:29pm, Saturday, 18'th Apr 2020
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
Denali Therapeutics Inc (NASDAQ:DNLI) Shares Sold by Goldman Sachs Group Inc.
09:52am, Thursday, 16'th Apr 2020
Goldman Sachs Group Inc. lowered its position in Denali Therapeutics Inc (NASDAQ:DNLI) by 3.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities &
Denali Therapeutics Inc. (DNLI): Are Hedge Funds Right About This Stock?
06:49pm, Wednesday, 15'th Apr 2020
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P; 500 Index wa
Denali Therapeutics (DNLI) Receives a Buy from Morgan Stanley
03:41pm, Wednesday, 15'th Apr 2020
In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Denali Therapeutics (DNLI), with a price target of $28.00. The
Denali Therapeutics (DNLI) Receives a Buy from Morgan Stanley
03:41pm, Wednesday, 15'th Apr 2020
In a report released today,
Matthew Harrison
from Morgan Stanley maintained a
Buy
rating on Denali Therapeutics (
DNLI
–
Research Report
), with a price target of
$28.00
. The company’s shares clo
